Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats cervical dystonia. Sold as Myobloc. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Botulinum Toxin Type B (sold as Myobloc), first approved Dec 8, 2000, with 1 new use approved and 0 published complete response letters.
First approved in Japan 121 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Nerbloc, new ingredientA drug with a new active ingredient indicated for the treatment of spasmodic torticollis (cervical dystonia). · Eisai Co., Ltd. · Jan 21, 2011
Clinical Trials
16 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
